Precision (DTIL) news
Recent news
Precision Biosciences - initial safety data from Function-DMD trial targeted for year-end 2026 - SEC filing
Precision BioSciences, Inc. (Nasdaq: DTIL) is advancing its Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, a first-in-class in vivo gene editing therapy for Duchenne muscular dystrophy (DMD). The trial, which began enrolling patients at Arkansas Children’s Hospital in April 2026, is designed…
AInvest Wire · Jul 1, 2026Precision Biosciences - extends term loan maturity date to December 31, 2029 - SEC filing
Precision BioSciences, Inc. (Nasdaq: DTIL) has filed a report with the U.S. Securities and Exchange Commission (SEC) indicating that it has extended the maturity date of its term loan to December 31, 2029. The filing, dated June 5, 2026, is part of the company’s changes in beneficial ownership .…
AInvest Wire · Jun 16, 2026Precision Biosciences Inc <DTIL.O>: Oppenheimer initiates coverage with outperform rating; price target $20
Precision Biosciences Inc (DTIL.O) has recently drawn attention following Oppenheimer's initiation of coverage with an "outperform" rating and a price target of $20 per share. The stock closed at $8.16 on June 8, 2026, reflecting a 5.23% decline from the previous day's close, although it has since…
AInvest Wire · Jun 9, 2026ImportantHon Hai Precision Industry (Foxconn) announced a strategic cooperation with Intel (INTC.O) to jointly develop an AI platform
AInvest Wire · Jun 4, 2026ImportantPrecision Biosciences: FDA fast track designation PBGene-DMD
AInvest Wire · Mar 9, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.